Izoprenalin Macure (Isoprenaline Hydrochloride)

Isoprenaline Hydrochloride is a non‑selective beta‑adrenergic agonist. It binds to β1 receptors in the heart, increasing cyclic AMP and producing faster heartbeats and stronger contractions. Simultaneously, it activates β2 receptors in the lungs, causing smooth‑muscle relaxation and bronchodilation. The combined actions enhance cardiac output and airway patency during acute crises.

The specific dose of Izoprenalin Macure is determined by the prescribing clinician based on the patient’s condition, weight, and response. Dosing is individualized and administered intravenously, often as a continuous infusion or titrated bolus under continuous cardiac and respiratory monitoring.

Safety data for isoprenaline hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case carefully and consider alternative therapies when appropriate.

To order Izoprenalin Macure, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

The primary alternatives to isoprenaline are dopamine and epinephrine. While dopamine has dose‑dependent effects on dopaminergic and adrenergic receptors, epinephrine stimulates both alpha and beta receptors, causing vasoconstriction as well as cardiac stimulation. Isoprenaline offers a more selective beta‑agonist profile, providing strong chronotropic and bronchodilator effects with less peripheral vasoconstriction, which can be advantageous in certain cardiac or respiratory emergencies.

Izoprenalin Macure should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

The medication is supplied as a sterile injection solution for intravenous use. It can be administered as a slow intravenous bolus or as a continuous infusion, depending on the clinical situation. Administration should occur under continuous cardiac and respiratory monitoring, with dosage adjustments made by the treating physician.

Serious risks include life‑threatening arrhythmias, myocardial ischemia, and severe hypotension. Patients may also develop excessive tachycardia or experience allergic reactions such as anaphylaxis. Immediate medical attention is required if any of these events occur, and continuous monitoring is essential during therapy.

Izoprenalin Macure is contraindicated in patients with known hypersensitivity to isoprenaline or any component of the formulation. It should be avoided in individuals with uncontrolled hypertension, severe coronary artery disease, or recent myocardial infarction unless the benefits clearly outweigh the risks and close monitoring is possible.